In recent years, three important topics have been frequently addressed in terms of scientific efforts and clinical management of the acute respiratory distress syndrome (ARDS): (1) the demand for a new definition which underlines more precisely the acute character of this syndrome [1], (2) the identification of the typical inflammatory pathways at onset of ARDS resulting in early management recommendations [2], and (3) a 'shift' from mortality as the golden standard of outcome parameter to the health-related quality of life of surviving ARDS patients [3]. The Berlin definition-despite some current critiques-enables a grading of the severity of the syndrome, i.e., severe ARDS means 'acute hypoxemic' and life-threatening, resulting in a high mortality rate. The three major causes of death in ARDS are refractory hypoxemia, multiple organ failure secondary to sepsis or hemodynamic compromise, or ventilator-induced lung injury. It has been shown that early ARDS is characterized by an overshooting systemic and pulmonary inflammatory response within 48 h triggered by various cytokines and inflammatory pathways. Furthermore there is an imbalance between excessive nuclear factor jB (NFjB) activity and deficient glucocorticoid receptor a (GCGRa) inducing resistance or insensitivity of the stressed host to endogenous corticosteroids [4]. As a result patients develop not only systemic inflammation and hemodynamic instability but also pulmonary inflammation and fibroproliferation with subsequent loss in lung function, increased mortality rate, and reduced health-related quality of life in survivors. Failure to repair tissue damage results in an ongoing and self-perpetuating inflammation: lung biopsies demonstrated fibroproliferation in 60 % of ARDS patients [5]. Typical clinical findings include persistent increased levels of inflammatory biomarkers, decreased compliance of the lungs, and reticular densities in radiographic imaging.
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Consequently, from recent interventional randomized studies we have learned that early therapeutic interventions in ARDS (lung [ultra-]protective strategies, adequate high PEEP, prone positioning) are critical points in setting the direction for survival: the first 48 h present the most vulnerable period in an ARDS's life! The early downregulation of inflammation is essential for reduction of the influx of neutrophils, monocytes, macrophages, and lymphocytes into the lung to restore the lung's homeostasis [6] .
What is the role of glucocorticoid (GC) therapy in early management of ARDS? Meduri and coworkers have impressively shown that low-dose GC have potent antiinflammatory and antifibroproliferative effects in this specific clinical setting [4] . Furthermore, the expression of high levels of type III procollagen in the immediate Intensive Care Med (2016) 42:918-920 DOI 10.1007/s00134-015-4162-x EDITORIAL phase of ARDS was identified as a strong predictor for fibrosis and it was argued that the beneficial effect of GC could be in preventing rather than in reversing lung fibrosis [7] . In a small randomized controlled trial [8] , early infusion (B72 h after onset of ARDS) of low-dose methylprednisolone was associated with significant improvement in pulmonary and extrapulmonary organ dysfunction. On the other hand, former studies investigating the effects of GC on a large patient database were not convincing: Bernard et al. administered four pulses of high-dose GC within 24 h after ARDS onset, but they found no benefit in terms of the 45-day mortality [9] , and the concept of 'supraphysiologic' high GC doses in this study was criticized in the aftermath. A randomized clinical trial led by the ARDS Network failed to show survival benefit of prolonged low-dose methylprednisolone in patients with persistent ARDS. Of note in this trial, 27 % of patients were recruited beyond 14 days from disease onset [10] .
A recent analysis of individual patient data from four randomized trials combined with a trial-level meta-analysis of the updated literature demonstrated that early and prolonged GC treatment accelerated resolution of ARDS, decreased hospital mortality and healthcare utilization without increasing the risk of infection [11] . The suggested mechanism underlying these beneficial effects is that prolonged treatment with low-dose GC may overcome ARDS-associated deficient GC-GRa activity [12] .
The take-home message from the meta-analysis by Meduri et al. is that glucocorticoids in severe ARDSearly, low-dosed, and prolonged-act as an important part of the management bundle (Fig. 1) . Indeed, the observed number needed to treat in this meta-analysis is rather low and side effects rather rare. Although retrospective analyses suggested negative effects of steroids (at various doses) on neuromuscular function, this aspect could not be confirmed by the prospective study of the ARDS Network [13] . Nevertheless, a number of unanswered issues include choice of drug (hydrocortisone or methylprednisolone), dose (moderate or low), and main mechanisms of genomic versus non-genomic effects.
In patients with refractory hypoxemia, an early and bundle-guided management is not only crucial for survival but also for quality of survival. Such a management should include lung protective ventilation, adequate PEEP, prone positioning, early and low-dose glucocorticoids (methylprednisolone initially 1 mg/kg/day, then dose tapering), and a short course of a short-acting neuromuscular blocker (Fig. 1) 
